ALVO•prnewswire•
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Summary
SAN FRANCISCO, Dec. 11, 2025 /PRNewswire/ -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 11, 2025 by prnewswire